Wilkinson JB, et al. - Experts reported the 6-year outcomes from a phase 1/2 trial using balloon-based brachytherapy to deliver accelerated partial breast irradiation (APBI) in 2 days. For this study, 45 patients with early-stage breast cancer received adjuvant APBI in 2 days with high-dose rate brachytherapy totaling 2800 cGy in four fractions (700 cGy BID) using a balloon-based applicator. Excellent clinical outcomes with tolerable chronic toxicities were seen with hypofractionated 2-day APBI using brachytherapy. Findings suggested 96%, 100%, and 93% to be the 6-year actuarial disease-free survival, cause-specific survival, and overall survival, respectively. Conservative measures were enough to heal 2 of the previously reported rib fractures. No ipsilateral breast tumor recurrence or regional nodal failure (6-year IBTR/RNF rate 0%) was noted; nonetheless, distant metastasis was experienced by two patients (4% at 6 years).